| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Duey Marc serves as a Director at APRE. Across recent SEC filings that breaks down to 3 buys and 1 sell.
Historically, Duey Marc's trades have earned a below-average insider score of 44/100 across 4 rated trades. Over a 12-month horizon, 33.3% of those trades were profitable, with an average 12-month return of -10.9%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 10, 2025 | APRE Aprea Therapeutics, Inc. | Director | Buy | 21,459 | $1.17 | $24,999.74 | +9.1% | -8.9% | - | |
| Oct 18, 2024 | APRE Aprea Therapeutics, Inc. | Director | Sell | 6,462 | $4.58 | $29,583.04 | -2.7% | -14.9% | -64.3% | |
| Oct 16, 2024 | APRE Aprea Therapeutics, Inc. | Director | Buy | 30,000 | $4.39 | $131,700.00 | +14.3% | +3.4% | -56.0% | |
| Oct 14, 2024 | APRE Aprea Therapeutics, Inc. | Director | Buy | 190 | $2.58 | $490.20 | - | +33.6% | -41.0% |